Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
Trovagene is a clinical-stage, oncology therapeutics company, taking a precision m...
Trovagene is a clinical-stage, oncology therape...
AzurRx BioPharma is a development stage biopharmaceutical company (NASDAQ: AZRX) f...
AzurRx BioPharma is a development stage biophar...
Novelion Therapeutics Inc. (âNovelion"), headquartered in Vancouver, British Col...
Novelion Therapeutics Inc. (âNovelion"), head...
Rubius Therapeutics developed our proprietary RED PLATFORMÂŽ to generate red blood...
Rubius Therapeutics developed our proprietary R...
Tyme Inc. is an emerging biotechnology company developing cancer therapeutics that...
Tyme Inc. is an emerging biotechnology company ...
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel ...
Ultragenyx is a biopharmaceutical company commi...
Arvinas is a biopharmaceutical company dedicated to improving the lives of patient...
Arvinas is a biopharmaceutical company dedicate...
Join the National Investor Network and get the latest information with your interests in mind.